Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, active-controlled, multicenter, international Phase 3 clinical trial comparing Gencaro with Toprol-XL (metoprolol succinate) for the prevention of recurrent AF or all-cause mortality (ACM) in HFrEF patients

Next Previous
Trial Profile

A double-blind, active-controlled, multicenter, international Phase 3 clinical trial comparing Gencaro with Toprol-XL (metoprolol succinate) for the prevention of recurrent AF or all-cause mortality (ACM) in HFrEF patients

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucindolol (Primary) ; Metoprolol succinate
  • Indications Atrial fibrillation; Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PRECISION-AF
  • Sponsors ARCA biopharma Inc

    • Most Recent Events

    • 11 May 2021 According to an ARCA biopharma Inc media release, the company continues to evaluate the potential timing for initiation of this trial relative to the COVID-19 pandemic and based on an improving clinical trial ecosystem, has begun organizing necessary trial logistics.
    • 05 Aug 2020 According to an ARCA biopharma Inc media release, initiation of the trial is on hold due to the ongoing COVID-19 pandemic and prioritizing the development of AB201. The company estimates that the trial could start in 2021; however, this estimate is subject to change due to the uncertainties of the ongoing COVID-19 pandemic and the availability of patients for non-COVID-19 related clinical trials.
    • 06 May 2020 Planned initiation date changed from 1 Oct 2019 to 1 Oct 2020. according to an ARCA biopharma Inc media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top